Medicare’s Payment Issues for Non-Utilized Organs

A recent audit conducted by the Department of Health and Human Services Office of Inspector General (OIG) has uncovered concerning discrepancies in Medicare payments. Over a period of six years, Medicare paid between $380 million to $400 million for organs that remained unused in Medicare-covered transplants.

This financial oversight has sparked questions regarding the reimbursement process for transplant centers and the possible conflict between federal guidance and statutory requirements.

Audit Findings

The findings of the audit reveal that Medicare has been reimbursing transplant centers based on a misunderstanding; the centers were compensated for organs intended for Medicare patients but, in reality, were either transplanted into non-Medicare patients or were left unused.

The audit states, “Medicare was paying acquisition costs under guidance that effectively assumed an organ transferred through the transplant system would ultimately be used for a Medicare patient. Sometimes it wasn’t,” explained Michael Ryan, a finance expert.

This misalignment between guidelines provided by the Centers for Medicare & Medicaid Services (CMS) and existing federal law has led taxpayers to cover the cost difference.

Impact and Concerns

The audit comes at a time when federal healthcare spending and the finances of Medicare are under legislative scrutiny. Transplantation is one of the costliest services covered by Medicare, with over $3 billion spent in 2023 alone on organ acquisition for about 39,000 organs.

With the audit indicating non-compliance with federal law, there’s potential that taxpayers could bear hundreds of millions in costs unnecessarily.

Understanding the Reimbursement Problem

Federal law generally limits Medicare reimbursements to organs used in Medicare-covered transplants. However, CMS guidance wrongly instructs centers to treat all transferred organs as if they will be used in Medicare procedures. In reality, some organs end up in patients without Medicare coverage, while others remain unused.

According to the OIG: Medicare incorrectly reimbursed approximately $2.8 million for 55 organs that should not have qualified for reimbursement.

• 43 of these organs were transplanted into non-Medicare patients.
• 12 organs were not transplanted at all.

Using this sample, Medicare’s excess expenditure was estimated at $380 million over the six-year review period.

Views on Alleged Waste

Despite these findings, opinions differ on the significance of the financial waste. Some argue, like Drew Powers of Powers Financial Group, that spread over six years, the waste is only about 2 percent of total organ transplant costs.

Powers stated, “Over six years, $18 billion was spent on organ transplants and $17.62 billion was used as intended. That seems reasonably efficient.”

Recommendations and Next Steps

The OIG has put forth recommendations to address the inconsistencies. It advises CMS to recover $154,210 in payments made to two transplant centers lacking adequate documentation. Additionally, it suggests a revision of Medicare’s guidance to ensure that only organs transplanted into Medicare patients are classified as Medicare-usable organs.